BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Gill J, Gorlick R. Advancing therapy for osteosarcoma. Nat Rev Clin Oncol 2021. [PMID: 34131316 DOI: 10.1038/s41571-021-00519-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Li D, Zhang C, Tai X, Xu D, Xu J, Sun P, Fan Q, Cheng Z, Zhang Y. 1064 nm activatable semiconducting polymer-based nanoplatform for NIR-II fluorescence/NIR-II photoacoustic imaging guided photothermal therapy of orthotopic osteosarcoma. Chemical Engineering Journal 2022;445:136836. [DOI: 10.1016/j.cej.2022.136836] [Reference Citation Analysis]
2 Fang Z, Mei W, Qu C, Lu J, Shang L, Cao F, Li F. Role of m6A writers, erasers and readers in cancer. Exp Hematol Oncol 2022;11:45. [PMID: 35945641 DOI: 10.1186/s40164-022-00298-7] [Reference Citation Analysis]
3 Du Y, Zeng X, Yu W, Xie W. A transmembrane protein family gene signature for overall survival prediction in osteosarcoma. Front Genet 2022;13:937300. [DOI: 10.3389/fgene.2022.937300] [Reference Citation Analysis]
4 Li R, Chen Z, Zhou Y, Maimaitirexiati G, Yan Q, Li Y, Maimaitiyimin A, Zhou C, Ren J, Liu C, Mainike A, Zhou P, Ding L. LncRNA SCAMP1 disrupts the balance between miR-26a-5p and ZEB2 to promote osteosarcoma cell viability and invasion. Front Oncol 2022;12:967000. [DOI: 10.3389/fonc.2022.967000] [Reference Citation Analysis]
5 Cheng J, Zhang Y, Wan R, Zhou J, Wu X, Fan Q, He J, Tan W, Deng Y. CEMIP Promotes Osteosarcoma Progression and Metastasis Through Activating Notch Signaling Pathway. Front Oncol 2022;12:919108. [DOI: 10.3389/fonc.2022.919108] [Reference Citation Analysis]
6 Ma Y, Tong C, Xu M, He H, Chen C, Zheng M. Bioinformatics Analysis Reveals an Association between Autophagy, Prognosis, Tumor Microenvironment, and Immunotherapy in Osteosarcoma. Journal of Oncology 2022;2022:1-15. [DOI: 10.1155/2022/4220331] [Reference Citation Analysis]
7 Zheng Y, Xu J, Lin J, Lin Y, Chen G. A Novel Necroptosis-Related lncRNA Signature for Osteosarcoma. Computational and Mathematical Methods in Medicine 2022;2022:1-9. [DOI: 10.1155/2022/8003525] [Reference Citation Analysis]
8 Wang J, Jin J, Chen T, Zhou Q. Curcumol Synergizes with Cisplatin in Osteosarcoma by Inhibiting M2-like Polarization of Tumor-Associated Macrophages. Molecules 2022;27:4345. [DOI: 10.3390/molecules27144345] [Reference Citation Analysis]
9 Zhou Y, Li G, Li H, Lai F, Duan P, Cheng M, Wang F. Epithelial to Mesenchymal Transition Relevant Subtypes with Distinct Prognosis and Responses to Chemo- or Immunotherapies in Osteosarcoma. Journal of Immunology Research 2022;2022:1-19. [DOI: 10.1155/2022/1377565] [Reference Citation Analysis]
10 Hu D, Lin K, Gao X, Zhou M, Geng H. EGCG regulated osteolytic microenvironment to enhance the antitumor effect of DOX on orthotopic osteosarcoma. Journal of Functional Foods 2022;94:105118. [DOI: 10.1016/j.jff.2022.105118] [Reference Citation Analysis]
11 White LM, Atinga A, Naraghi AM, Lajkosz K, Wunder JS, Ferguson P, Tsoi K, Griffin A, Haider M. T2-weighted MRI radiomics in high-grade intramedullary osteosarcoma: predictive accuracy in assessing histologic response to chemotherapy, overall survival, and disease-free survival. Skeletal Radiol 2022. [PMID: 35778618 DOI: 10.1007/s00256-022-04098-2] [Reference Citation Analysis]
12 Shao X, Zhan S, Quan Q, Shen Y, Chen S, Zhang X, Li R, Liu M, Cao L. Clinical significance of B7-H3 and HER2 co-expression and therapeutic value of combination treatment in gastric cancer. Int Immunopharmacol 2022;110:108988. [PMID: 35777267 DOI: 10.1016/j.intimp.2022.108988] [Reference Citation Analysis]
13 Du Y, Zhang Z, Yang Y, Liu T, Chen T, Li X. Highly active selenium nanotherapeutics combined with metformin to achieve synergistic sensitizing effect on NK cells for osteosarcoma therapy. Nanophotonics 2022;0. [DOI: 10.1515/nanoph-2022-0289] [Reference Citation Analysis]
14 Luo P, Zhang YD, He F, Tong CJ, Liu K, Liu H, Zhu SZ, Luo JZ, Yuan B. HIF-1α-mediated augmentation of miRNA-18b-5p facilitates proliferation and metastasis in osteosarcoma through attenuation PHF2. Sci Rep 2022;12:10398. [PMID: 35729160 DOI: 10.1038/s41598-022-13660-w] [Reference Citation Analysis]
15 Chen Y, Wu X, Li J, Jiang Y, Xu K, Su J. Bone-Targeted Nanoparticle Drug Delivery System: An Emerging Strategy for Bone-Related Disease. Front Pharmacol 2022;13:909408. [PMID: 35712701 DOI: 10.3389/fphar.2022.909408] [Reference Citation Analysis]
16 Lv B, Liu F, Gou F, Wu J. Multi-Scale Tumor Localization Based on Priori Guidance-Based Segmentation Method for Osteosarcoma MRI Images. Mathematics 2022;10:2099. [DOI: 10.3390/math10122099] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
17 Fan L, Peng C, Zhu X, Liang Y, Xu T, Xu P, Wu S. Dihydrotanshinone I Enhances Cell Adhesion and Inhibits Cell Migration in Osteosarcoma U-2 OS Cells through CD44 and Chemokine Signaling. Molecules 2022;27:3714. [PMID: 35744840 DOI: 10.3390/molecules27123714] [Reference Citation Analysis]
18 Zeng Z, Li W, Zhang D, Zhang C, Jiang X, Guo R, Wang Z, Yang C, Yan H, Zhang Z, Wang Q, Huang R, Zhao Q, Li B, Hu X, Gao L. Development of a Chemoresistant Risk Scoring Model for Prechemotherapy Osteosarcoma Using Single-Cell Sequencing. Front Oncol 2022;12:893282. [PMID: 35664733 DOI: 10.3389/fonc.2022.893282] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
19 Chen T, Liu J, Zhang H, Li J, Shang G. Long Intergenic Noncoding RNA00265 Enhances Cell Viability and Metastasis via Targeting miR-485-5p/USP22 Axis in Osteosarcoma. Front Oncol 2022;12:907472. [DOI: 10.3389/fonc.2022.907472] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
20 Wang G, Zhang X, Feng W, Wang J. Prediction of Prognosis and Immunotherapy of Osteosarcoma Based on Necroptosis-Related lncRNAs. Front Genet 2022;13:917935. [DOI: 10.3389/fgene.2022.917935] [Reference Citation Analysis]
21 Chen Y, Li C, Wang X, Liu Z, Ren Z. Development of a Simple Risk Model to Predict Mortality in Patients With Osteosarcoma of the Extremity. Front Med 2022;9:852529. [DOI: 10.3389/fmed.2022.852529] [Reference Citation Analysis]
22 Djuričić GJ, Ahammer H, Rajković S, Kovač JD, Milošević Z, Sopta JP, Radulovic M. Directionally Sensitive Fractal Radiomics Compatible With Irregularly Shaped Magnetic Resonance Tumor Regions of Interest: Association With Osteosarcoma Chemoresistance. J Magn Reson Imaging 2022. [PMID: 35561019 DOI: 10.1002/jmri.28232] [Reference Citation Analysis]
23 Zheng D, Wei Z, Guo W. Identification of a Solute Carrier Family-Based Signature for Predicting Overall Survival in Osteosarcoma. Front Genet 2022;13:849789. [PMID: 35518353 DOI: 10.3389/fgene.2022.849789] [Reference Citation Analysis]
24 Yuan Y, Li D, Hu X, Li Y, Yi W, Li P, Zhao Y, Li Z, Yu A, Jian C, Yu A. Chidamide augment sorafenib-derived anti-tumor activities in human osteosarcoma cells lines and xenograft mouse model. Med Oncol 2022;39:87. [PMID: 35478053 DOI: 10.1007/s12032-022-01684-1] [Reference Citation Analysis]
25 Liang L, Li G, Ye X. The Roles of KIFC1 in the Development of Osteosarcoma: Characterization of Potential Therapeutic Targets. Computational and Mathematical Methods in Medicine 2022;2022:1-10. [DOI: 10.1155/2022/5039134] [Reference Citation Analysis]
26 Tian S, Liu S, Qing X, Lin H, Peng Y, Wang B, Shao Z. A predictive model with a risk-classification system for cancer-specific survival in patients with primary osteosarcoma of long bone. Translational Oncology 2022;18:101349. [DOI: 10.1016/j.tranon.2022.101349] [Reference Citation Analysis]
27 Lu Y, Zhang J, Chen Y, Kang Y, Liao Z, He Y, Zhang C. Novel Immunotherapies for Osteosarcoma. Front Oncol 2022;12:830546. [DOI: 10.3389/fonc.2022.830546] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
28 Nakano K. Challenges of Systemic Therapy Investigations for Bone Sarcomas. Int J Mol Sci 2022;23:3540. [PMID: 35408900 DOI: 10.3390/ijms23073540] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
29 Qiu C, Liu T, Luo D, Luan D, Cheng L, Wang S. Novel Therapeutic Savior for Osteosarcoma: The Endorsement of Ferroptosis. Front Oncol 2022;12:746030. [DOI: 10.3389/fonc.2022.746030] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
30 Jiang X, Zeng F, Yang X, Jian C, Zhang L, Yu A, Lu A. Injectable self-healing cellulose hydrogel based on host-guest interactions and acylhydrazone bonds for sustained cancer therapy. Acta Biomater 2022;141:102-13. [PMID: 34990813 DOI: 10.1016/j.actbio.2021.12.036] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
31 Zhang Y, Ning R, Wang W, Zhou Y, Chen Y. Synthesis of Fe3O4/PDA Nanocomposites for Osteosarcoma Magnetic Resonance Imaging and Photothermal Therapy. Front Bioeng Biotechnol 2022;10:844540. [DOI: 10.3389/fbioe.2022.844540] [Reference Citation Analysis]
32 Liu J, Shang G. The Roles of Noncoding RNAs in the Development of Osteosarcoma Stem Cells and Potential Therapeutic Targets. Front Cell Dev Biol 2022;10:773038. [PMID: 35252166 DOI: 10.3389/fcell.2022.773038] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
33 Zhang Y, Xu W, Wang Y, Li J, He G, Guan M, Zeng X, Bian W, Song Y, Liu J. Oncogenic lncRNA ZNFX1 antisense RNA 1 promotes osteosarcoma cells proliferation and metastasis by stabilizing serine and arginine‑rich splicing factor 3. Bioengineered 2022;13:5962-74. [DOI: 10.1080/21655979.2022.2036900] [Reference Citation Analysis]
34 He P, Xu S, Guo Z, Yuan P, Liu Y, Chen Y, Zhang T, Que Y, Hu Y. Pharmacodynamics and pharmacokinetics of PLGA-based doxorubicin-loaded implants for tumor therapy. Drug Deliv 2022;29:478-88. [PMID: 35147071 DOI: 10.1080/10717544.2022.2032878] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
35 Wang G, Cao L, Jiang Y, Zhang T, Wang H, Wang Z, Xu J, Mao M, Hua Y, Cai Z, Ma X, Hu S, Zhou C. Anlotinib Reverses Multidrug Resistance (MDR) in Osteosarcoma by Inhibiting P-Glycoprotein (PGP1) Function In Vitro and In Vivo. Front Pharmacol 2021;12:798837. [PMID: 35111065 DOI: 10.3389/fphar.2021.798837] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
36 Sun X, Shan HJ, Yin G, Zhang XY, Huang YM, Li HJ. The anti-osteosarcoma cell activity by the sphingosine kinase 1 inhibitor SKI-V. Cell Death Discov 2022;8:48. [PMID: 35115496 DOI: 10.1038/s41420-022-00838-4] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
37 Feng X, Zhao Z, Zhao Y, Song Z, Ma Y, Wang W. Development of Personalized Signature Based on the Immune Landscape to Predict the Prognosis of Osteosarcoma and the Response to Immunotherapy and Targeted Therapy. Front Mol Biosci 2022;8:783915. [DOI: 10.3389/fmolb.2021.783915] [Reference Citation Analysis]
38 Lin J, Xu A, Jin J, Zhang M, Lou J, Qian C, Zhu J, Wang Y, Yang Z, Li X, Yu W, Liu B, Tao H. MerTK-mediated efferocytosis promotes immune tolerance and tumor progression in osteosarcoma through enhancing M2 polarization and PD-L1 expression. Oncoimmunology 2022;11:2024941. [PMID: 35036076 DOI: 10.1080/2162402X.2021.2024941] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
39 Lee CW, Huang CC, Chi MC, Lee KH, Peng KT, Fang ML, Chiang YC, Liu JF. Naringenin Induces ROS-Mediated ER Stress, Autophagy, and Apoptosis in Human Osteosarcoma Cell Lines. Molecules 2022;27:373. [PMID: 35056691 DOI: 10.3390/molecules27020373] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
40 Broqueza J, Prabaharan CB, Allen KJH, Jiao R, Fisher DR, Dickinson R, MacDonald-Dickinson V, Uppalapati M, Dadachova E. Radioimmunotherapy Targeting IGF2R on Canine-Patient-Derived Osteosarcoma Tumors in Mice and Radiation Dosimetry in Canine and Pediatric Models. Pharmaceuticals (Basel) 2021;15:10. [PMID: 35056067 DOI: 10.3390/ph15010010] [Reference Citation Analysis]
41 Han QC, Zhang XY, Yan PH, Chen SF, Liu FF, Zhu YR, Tian Q. Identification of mitochondrial RNA polymerase as a potential therapeutic target of osteosarcoma. Cell Death Discov 2021;7:393. [PMID: 34907167 DOI: 10.1038/s41420-021-00780-x] [Reference Citation Analysis]
42 Hecker-Nolting S, Langer T, Blattmann C, Kager L, Bielack SS. Current Insights into the Management of Late Chemotherapy Toxicities in Pediatric Osteosarcoma Patients. Cancer Manag Res 2021;13:8989-98. [PMID: 34880679 DOI: 10.2147/CMAR.S287908] [Reference Citation Analysis]
43 Nava-Tapia DA, Cayetano-Salazar L, Herrera-Zúñiga LD, Bello-Martínez J, Mendoza-Catalán MA, Navarro-Tito N. Brazilin: Biological activities and therapeutic potential in chronic degenerative diseases and cancer. Pharmacol Res 2021;175:106023. [PMID: 34883212 DOI: 10.1016/j.phrs.2021.106023] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
44 Omer N, Nicholls W, Ruegg B, Souza-Fonseca-Guimaraes F, Rossi GR. Enhancing Natural Killer Cell Targeting of Pediatric Sarcoma. Front Immunol 2021;12:791206. [PMID: 34804076 DOI: 10.3389/fimmu.2021.791206] [Reference Citation Analysis]
45 Chen G, Yin Y, Chen C. Limb-salvage surgery using personalized 3D-printed porous tantalum prosthesis for distal radial osteosarcoma: A case report. Medicine (Baltimore) 2021;100:e27899. [PMID: 34797342 DOI: 10.1097/MD.0000000000027899] [Reference Citation Analysis]
46 Tang Y, Liu Y, Huang X, Li P, Chen Y. DNA Damage Response Genes in Osteosarcoma. Journal of Oncology 2021;2021:1-9. [DOI: 10.1155/2021/9365953] [Reference Citation Analysis]
47 Serra M, Hattinger CM, Pasello M, Casotti C, Fantoni L, Riganti C, Manara MC. Impact of ABC Transporters in Osteosarcoma and Ewing's Sarcoma: Which Are Involved in Chemoresistance and Which Are Not? Cells 2021;10:2461. [PMID: 34572110 DOI: 10.3390/cells10092461] [Reference Citation Analysis]
48 Yi Y, Woo YM, Hwang KH, Kim HS, Lee SH. Niclosamide and Pyrvinium Are Both Potential Therapeutics for Osteosarcoma, Inhibiting Wnt-Axin2-Snail Cascade. Cancers (Basel) 2021;13:4630. [PMID: 34572856 DOI: 10.3390/cancers13184630] [Reference Citation Analysis]
49 Wang JH, Zeng Z, Sun J, Chen Y, Gao X. A novel small-molecule antagonist enhances the sensitivity of osteosarcoma to cabozantinib in vitro and in vivo by targeting DNMT-1 correlated with disease severity in human patients. Pharmacol Res 2021;173:105869. [PMID: 34481973 DOI: 10.1016/j.phrs.2021.105869] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]